Taro's Keveyis 50 mg Tablets Available for Treatment of Primary Hyperkalemic, Hypokalemic Periodic Paralysis

Taro Pharmaceutical Industries Ltd.

announced today that Keveyis™ (dichlorphenamide) 50 mg Tablets, the first medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary hyperkalemic and hypokalemic periodic paralysis and related variants, is now available for appropriate patients through its specialty pharmacy partner, Diplomat. Periodic paralysis is a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis.[1] It is estimated to affect approximately 5,000 people in the United States, up to 70 percent of which are currently undiagnosed.[2] "Receiving an accurate diagnosis is a significant hurdle faced by many people living with this often debilitating disease," said Kal Sundaram,